Gennex Laboratories Limited (BOM:531739)

Market Cap	2.79B -13.0%
Revenue (ttm)	1.49B +32.8%
Net Income	185.52M +7.3%
EPS	0.78 +12.0%
Shares Out	227.45M
PE Ratio	15.81
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	326,551
Average Volume	404,841
Open	12.36
Previous Close	12.44
Day's Range	12.13 - 12.56
52-Week Range	10.84 - 17.25
Beta	0.33
RSI	42.32
Earnings Date	Feb 14, 2026

About Gennex Laboratories

Gennex Laboratories Limited manufactures and sells bulk drugs, intermediates, and biotech products. The company offers Guaifenesin, an expectorant used as a mucolyte; Methocarbamol for skeletal muscle relaxant; Fexofenadine Hcl for treating antihistamines; Phenazopyridine Hcl for the treatment of urinary tract analgesic; Fluconazole for antifungals; Melitracen Hcl for treating tricyclic antidepressant; Sertraline Hcl, a selective serotonin reuptake inhibitor; Chlorphenesin and Mephenesin for muscle relaxant; and Allopurinol, a xanthine oxidase ...

• Industry: Pharmaceutical Preparations
• Founded: 1985
• Employees: 115
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 531739

Financial Performance

In fiscal year 2025, Gennex Laboratories's revenue was 1.38 billion, an increase of 59.03% compared to the previous year's 867.14 million. Earnings were 181.23 million, an increase of 37.55%.